PapersPMID:18381567
Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial.
What moved
1 findingHow to read these marks →- Increases all-cause mortality
very limited
“All-cause mortality was higher among patients assigned to MC-1 than placebo at 4 days (1.0% vs 0.3%; P = .03) but was similar at 30 days (1.9% vs 1.5%; P = .44).”
- Study
- RCT
- Duration
- 4 days
- Dose studied
- MC-1 250 mg/d immediately before and for 30 days after surgery
- Population
- Intermediate- to high-risk patients undergoing CABG surgery with cardiopulmonary bypass; mortality at 4 days
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- intermediate- to high-risk patients undergoing CABG surgery with cardiopulmonary bypass
- Participants
- 3,023
- Comparator
- placebo
- Duration
- 30 days
- Endpoints measured
- 4